	US 12,187,798 B2
	LAG-3 binding members
Mihriban Tuna, Cambridge (GB); Francisca Wollerton van Horck, Cambridge (GB); Katy Louise Everett, Cambridge (GB); Miguel Gaspar, Cambridge (GB); Matthew Kraman, Cambridge (GB); Katarzyna Kmiecik, Cambridge (GB); and Natalie Fosh, Cambridge (GB)
Assigned to INVOX PHARMA LIMITED, London (GB)
Filed by F-star Therapeutics Limited, Cambridge (GB)
Filed on Nov. 23, 2021, as Appl. No. 17/534,315.
Application 17/534,315 is a continuation of application No. 16/311,596, granted, now 11,214,618, previously published as PCT/EP2017/065052, filed on Jun. 20, 2017.
Claims priority of provisional application 62/352,470, filed on Jun. 20, 2016.
Prior Publication US 2022/0185890 A1, Jun. 16, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 16/28 (2006.01); A61P 35/00 (2006.01); A61K 39/00 (2006.01)

CPC C07K 16/2818 (2013.01) [A61P 35/00 (2018.01); C07K 16/2866 (2013.01); C07K 16/2896 (2013.01); A61K 2039/505 (2013.01); A61K 2039/5152 (2013.01); C07K 2317/31 (2013.01); C07K 2317/33 (2013.01); C07K 2317/34 (2013.01); C07K 2317/526 (2013.01); C07K 2317/53 (2013.01); C07K 2317/73 (2013.01); C07K 2317/74 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01); C07K 2318/20 (2013.01)]

24 Claims

1. A specific binding member which binds to lymphocyte-activation gene 3 (LAG-3), comprising a LAG-3 antigen-binding site located in a CH3 domain of the specific binding member, wherein the LAG-3 antigen-binding site comprises the amino acid sequences WDEPWGED (SEQ ID NO: 1), SNGQPENNY (SEQ ID NO: 2) and PYDRWVWPDE (SEQ ID NO: 3).